awmsg logo



sofosbuvir/velpatasvir (Epclusa®)


Reference No. 2417

Publication date:
21/11/2016


Appraisal information

sofosbuvir/velpatasvir (Epclusa®) 400 mg/100 mg film-coated tablet


Company: Gilead Sciences Ltd
BNF category: Infections
NMG meeting date: 05/10/2016
AWMSG meeting date: 09/11/2016
   
   
Submission Type: Directed
Status: Superseded
Advice No: 3116
Ministerial ratification: 18/11/2016

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA430) NICE GUIDANCE ISSUED JANUARY 2017 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download